New Data on Hydroxychloroquine Shows Little Benefit

New clinical trial data from China suggest that hydroxychloroquine may not be a useful treatment for COVID-19 patients.

The study of 150 hospitalized COVID-19 patients found that adding the antimalarial drug did not improve upon the standard-of-care.

The malaria drug did appear to reduce inflammation, but more adverse events were observed in the hydroxychloroquine group vs. the standard-of-care cohort.